TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00725985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine tablets were administered until CDMS conversion, whichever occur first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine tablets were administered until CDMS conversion, whichever occur first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine tablets were administered until CDMS conversion, whichever occur first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine tablets were administered until CDMS conversion, whichever occur first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine tablets were administered until CDMS conversion, whichever occur first.
Study: NCT02786732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 210mg Brodalumab
Description: Brodalumab 210mg administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 210mg Brodalumab
Description: Brodalumab 210mg administered subcutaneously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 210mg Brodalumab
Description: Brodalumab 210mg administered subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 140mg Brodalumab
Description: Brodalumab 140mg administered subcutaneously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab 45mg or 90mg adminstered subcutaneously
Study: NCT00725985

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to cladribine tablets were administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to cladribine tablets were administered.
Study: NCT00739973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02786732

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study: NCT00725985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to cladribine tablets were administered.
Study: NCT03741894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodoform
Description: Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wound closure using sutures
Description: Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
Study: NCT00739973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg tablet
Study: NCT03741894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wound closure using sutures
Description: Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wound closure using sutures
Description: Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
Study: NCT02215993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
Study: NCT02215993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
Study: NCT00400829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study: NCT03468699

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous BMMC transplantation
Description: Stem cell transplantation
Study: NCT03750032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stapler appendectomy
Description: The patients randomised for this intervention will undergo stapler appendectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoloop
Description: The patients randomised for this intervention will undergo appendicular stump closure using Endoloop.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hem-O-Lock
Description: The patients randomised for this intervention will undergo appendicular stump closure using Hem-O-Lock.
Study: NCT02349334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Tibial Nerve Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous Tibial Nerve Stimulation
Study: NCT02686606

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vital 1.5
Description: Oral nutritional supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Plus
Description: Oral nutritional supplement
Study: NCT03420131

Intervention type: DIAGNOSTIC_TEST
Intervention: QFR and iFR
Description: iFR® (CE-Marked) is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option.~QFR® (CE-Marked) is an angio-based FFR estimation using the analytical Software QAngio XA 3D from Medis medical imaging B.V., The Netherland
Study: NCT06105424

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Permeability Assessment
Description: A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Permeability Assessment
Description: A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Permeability Assessment
Description: A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Permeability Assessment
Description: A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.
Study: NCT01912430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICC (Integrated Care Coaching) Intervention Group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICC (Integrated Care Coaching) Intervention Group
Study: NCT00739973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 150/5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 150/10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/10 mg tablet
Study: NCT03932331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib 100 mg orally twice daily
Study: NCT02220725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02418455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX003
Description: solution for intravenous infusion
Study: NCT01397617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NobelActive Internal implant
Description: Dental implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NobelActive External implant
Description: Dental implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NobelReplace Tapered Groovy implant
Description: Dental implant
Study: NCT01467479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly Active Antiretroviral Therapy (HAART)
Description: Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly Active Antiretroviral Therapy (HAART)
Description: Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly Active Antiretroviral Therapy (HAART)
Description: Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
Study: NCT02788799

Intervention type: OTHER
Intervention: Standard 12-Lead ECG
Description: Conventional record of Standard 12-lead ECG in every patient with suspect of acute coronary syndrome.

Intervention type: OTHER
Intervention: Standard 12-Lead ECG
Description: Conventional record of Standard 12-lead ECG in every patient with suspect of acute coronary syndrome.

Intervention type: OTHER
Intervention: Posterior ECG Leads
Description: Recording posterior ECG leads (V7, V8 and V9) in addition to standard 12-lead ECG for identifying STEMI involving left cirumflex coronary artery.
Study: NCT03186599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low adherence intervention group
Description: Monthly, the study coordinator will give calls to encourage physical activities and medication adherence using MEMS and WALKON activity data.
Study: NCT03389087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and Etoposide Capsule
Description: Apatinib 250mg/qd，po, A course of treatment need 28 days. Etoposide Capsule 25mg/d，po, from day 1-day 21.
Study: NCT01010750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate (LDX)
Description: Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release Mixed Amphetamine Salts (MAS-IR)
Description: Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LDX Placebo + MAS-IR Placebo
Description: Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
Study: NCT00108576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: anticonvulsant; mood stabilizer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Look-a-like placebo
Study: NCT02510261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patisiran
Description: Patisiran was administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patisiran
Description: Patisiran was administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patisiran
Description: Patisiran was administered IV.
Study: NCT01215071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: limited lymphadenectomy
Description: Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extended lymphadenectomy
Description: Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
Study: NCT00777933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study: NCT04109534

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Bronchial allergen provocation (BAP)
Description: Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc... until the FEV1 decreases 20% below the initial FEV1-value

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bronchial allergen provocation (BAP)
Description: Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc... until the FEV1 decreases 20% below the initial FEV1-value

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Nasal provocation test (NPT)
Description: Dermatophagoides farina will be administered in both nostrils

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nasal provocation test (NPT)
Description: Dermatophagoides farina will be administered in both nostrils

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Methacholine test
Description: Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine test
Description: Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Peak nasal expiratory flow (PNIF)
Description: Comparison of peak nasal expiratory flow (PNIF) after NPT between groups

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Peak nasal expiratory flow (PNIF)
Description: Comparison of peak nasal expiratory flow (PNIF) after NPT between groups
Study: NCT03727854

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Premeal protein enriched bar
Description: Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary modification
Description: Subjects in this group will follow diabetes diet education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary modification
Description: Subjects in this group will follow diabetes diet education.
Study: NCT04392713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin 6 MG Oral Tablet (2 tablets)
Description: 12 mg single dose of Ivermectin will be given to intervention arm
Study: NCT04286529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol capsules
Description: 0.25micrograms, taken daily for eight weeks, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol capsules
Description: 0.25micrograms, taken daily for eight weeks, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo will be created to mimic the appearance of the study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo will be created to mimic the appearance of the study drug
Study: NCT03408925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: The orienteerers are asked to perform specific exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function. Each second week the exercises' difficulty level is increased.
Study: NCT01086527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg tablet of montelukast (Singulair)
Description: Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
Study: NCT02448381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGX301 (synthetic hypericin)
Description: 0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
Study: NCT02150707

Intervention type: DRUG
Intervention: Dipeptidyl-Peptidase IV Inhibitors
Description: Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia

Intervention type: DRUG
Intervention: Glucagon-Like Peptide 1
Description: Glucagon-Like Peptide 1 to treat hyperglycaemia
Study: NCT02040935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 600 mg SC Q3W by SID
Study: NCT03999021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC effervescent tablets
Description: After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).
Study: NCT03070106

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Functional Medicine
Description: Subjects randomized to the Functional Medicine plus the usual care arm will receive nutrition therapy and dietary supplements. Functional Medicine labs will be used in part to determine which supplements will be prescribed.
Study: NCT03748914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: After delivery of the neonate via caesarean section the umbilical cord will be clamped within 30 seconds and cut long at least 30 cm by the obstetrician. The neonate is then placed under an overhead heater by the midwife. There, the umbilical cord must be untwisted and held in a vertical position. It is milked once by the neonatologist towards the baby at a speed of approximately 10 cm/s and then clamped 3 cm from the umbilicus by one member of the clinical team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
Study: NCT00777933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Study: NCT02358733

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-cytoplasmic Sperm Injection
Description: Selection of sperm at 400x for sperm injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-cytoplasmic Morphologically-selected Sperm Injection
Description: Selection of sperm at 6000x for sperm injection
Study: NCT01678651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation with human FSH
Description: Human FSH

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation with recombinant FSH
Description: Recombinant FSH
Study: NCT01332786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~* Level 1: 50 mg daily x 10 doses; 1 week rest~* Level 2: 100 mg daily x 10 doses; 1 week rest~* Level 3: 150 mg daily x 10 doses; 1 week rest~* Level 4: 200 mg daily x 10 doses 1 week rest~* Level 5: 250 mg daily x 10 doses; 1 week rest~* Level 6: 300 mg daily x 10 doses; 1 week rest~* Level 7: 350 mg daily x 10 doses; 1 week rest
Study: NCT03470584

Intervention type: OTHER
Intervention: Diet Exposure
Description: Vegetarian diet vs nonvegetarian diet
Study: NCT03344484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical approach
Description: Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical approach
Description: Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion
Study: NCT03359837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (HOE901)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection